ArticleBMC pediatrics2025
Diagnosis of EBV and HCMV infections in pediatric heart transplant recipients.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundViral infections, including human cytomegalovirus (HCMV) and Epstein–Barr Virus (EBV), are significant agents that can cause serious complications and death in heart transplant recipients. This study aims to detect CMV and EBV infections in pediatric heart transplant recipients.
methodsWe conducted a cross-sectional study involving 28 hospitalized children who were candidates for heart transplantation. Plasma samples were collected at three time points: during surgery, one month after transplantation, and two months after transplantation. Urine samples were collected two months post-transplant. Heart tissue specimens from donors were taken from the aorta wall, pulmonary artery, and left atrium. Molecular tests were performed to detect EBV and CMV infections and viral loads. The patients’ clinical information was recorded and analyzed.
resultsAll 28 patients were CMV seropositive (100%), and 64.28% had EBV-IgG. CMV infection was detected in 10.7%, 7.1%, and 7.1% of plasma samples at the three time points, respectively, and in 7.1% of urine samples two months post-transplant. EBV infection in plasma was more frequent than CMV, with detection rates of 25%, 22.2%, and 25% at the three time points, respectively. Two recipients (7.1%) received CMV-infected heart tissue, and four patients (14.3%) received EBV-infected heart tissue.
conclusionThe immunosuppressive state in solid organ transplantation can trigger the reactivation and re-infection of CMV and EBV, leading to CMV disease and EBV-associated complications in heart transplant recipients. Our findings emphasize the need for long-term monitoring, effective prophylactic strategies, and a balanced approach to immunosuppression to mitigate the risks associated with these viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.